GeoVax Labs’ (GOVX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $18.00 price target on the stock.

GOVX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Trading Up 0.4 %

Shares of NASDAQ GOVX traded up $0.01 during trading hours on Wednesday, hitting $2.25. The stock had a trading volume of 219,437 shares, compared to its average volume of 2,357,253. The firm’s 50-day moving average price is $2.35 and its two-hundred day moving average price is $2.75. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same quarter in the prior year, the business posted ($4.80) EPS. On average, research analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.